Compare PPIH & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPIH | GANX |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.6M | 159.2M |
| IPO Year | N/A | 2021 |
| Metric | PPIH | GANX |
|---|---|---|
| Price | $31.51 | $3.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 95.5K | ★ 2.2M |
| Earning Date | 12-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $200,783,000.00 | N/A |
| Revenue This Year | $25.58 | N/A |
| Revenue Next Year | $15.38 | N/A |
| P/E Ratio | $18.83 | ★ N/A |
| Revenue Growth | ★ 30.74 | N/A |
| 52 Week Low | $8.81 | $1.41 |
| 52 Week High | $36.48 | $4.34 |
| Indicator | PPIH | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 57.10 | 47.41 |
| Support Level | $31.81 | $2.98 |
| Resistance Level | $33.77 | $3.32 |
| Average True Range (ATR) | 1.75 | 0.46 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 39.68 | 41.59 |
Perma-Pipe International Holdings Inc is engaged in the manufacture and sale of products in the reportable segment of Piping Systems. The company engineers, designs, manufactures, and sells specialty piping systems and leak detection systems. Specialty piping systems include insulated and jacketed district heating and cooling piping systems for efficient energy distribution from central energy plants to multiple locations, primary and secondary containment piping systems for transporting chemicals, hazardous fluids, and petroleum products, and the coating and insulation of oil and gas gathering and transmission pipelines. It operates in the United States, Canada, the Middle East, Europe, India, and other countries.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.